All entries for: Immune Diseases

November 8, 2022

Protagonist Therapeutics

Discontinued Drug, Discontinued Research

Newark, CA
51-200 employees
51-200 employees

Paused trials of rusfertide in additional indications: “In keeping with our organizational prioritization of rusfertide in PV, plans to initiate trials of rusfertide in additional disease indications have been paused. This decision was influenced in part by the recent enactment of the Inflation Reduction Act in the United States and includes previously planned trials of rusfertide in the subset of hereditary hemochromatosis patients with chronic arthropathy”

1 Discontinued Drug: rusfertide (biologic)
1 Discontinued Research Program

Disease Area: Immune Diseases
Drug Type: Biologic
Scroll to Top